Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

(2019) Xiaobin Gu et al.   Cancer Cell International

First-line Pembrolizumab vs. Pembrolizumab plus Chemotherapy vs. Chemotherapy alone in Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis

(2019) Ryul Kim et al.   Clinical Lung Cancer

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

(2019) Urania Dafni et al.   LUNG CANCER

Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression

(2019) Rafael Grochot et al.   Cancer Management and Research

Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma

(2019) EIJI FUKUOKA et al.   ANTICANCER RESEARCH

Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study

(2019) Lei Li et al.   International Journal of Clinical Oncology

PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma

(2019) Ozlen Saglam et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer

(2018) Ying Meng et al.   Journal of Cancer

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

(2018) Junghoon Shin et al.   Cancer Research and Treatment

Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients

(2017) Feng Yang-Chun et al.   MEDICINE

Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity

(2017) Chaoqi Liu et al.   Molecular Medicine Reports

Tumor Microenvironment and Differential Responses to Therapy

(2017) Eishu Hirata et al.   Cold Spring Harbor Perspectives in Medicine

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness

(2017) Edith Borcoman et al.   Therapeutic Advances in Medical Oncology

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

(2016) S J L Mesnage et al.   ANNALS OF ONCOLOGY

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix

(2016) A Marijne Heeren et al.   MODERN PATHOLOGY

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

(2016) Jamaal A Rehman et al.   MODERN PATHOLOGY

PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials

(2016) Angela M Hong et al.   Oncotarget

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY